Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
With
Otsuka Pharmaceutical Co., Ltd.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients will be recruited among those who complete treatment with aripiprazole in Study 14724A / NCT01795547.
The patient is judged to potentially benefit from 24-week treatment with aripiprazole once-monthly according to the clinical opinion of the investigator.
The patient agrees to protocol-defined use of effective contraception.
You may not be if
The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14724A / NCT01795547.
The patient has a clinically significant unstable illness diagnosed during Study 14724A / NCT01795547.
The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).
The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability or efficacy, or interfere with the conduct or interpretation of the study.
The patient has one or more clinical laboratory test values outside the reference range, based on the blood or urine samples taken during the conduct of Study 14724A / NCT01795547 that are, in the investigator's opinion, of potential risk to the patient's safety.
The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
Clareo Health | Aripiprazole Once-monthly in Patients With Schizophrenia
